BIORASI, LLC
AVENTURA, FLORIDA

Clinical Research Optimized™ is more than a tagline. It’s who we are, what we do, how we do it, why we do it that way, and where we work. It’s a demand we make of ourselves, as well as a promise to the sponsors that work with us. Clinical Research Optimized™ is a combination of our people, our processes, and our platform to produce success for our sponsors in even the most challenging trials. Biorasi was established in 2002 to help pharmaceutical and biotechnology companies accelerate the process of bringing safe, effective and reliable therapies to market. Successful technology entrepreneur and company founder Boris N. Reznik, Ph.D., and his team analyzed the innovative therapeutics industry and realized much could be gained from applying sophisticated strategies, professional project management, information technology solutions, and dedicated project teams. As a result, Dr. Reznik and his team developed and introduced TALOS™, a unique system that combines a powerful technology platform, industry-leading training, and employee-owned culture focused on delivering impressive results for leading pharmaceutical and biotechnology companies. The goal and founding mission is to ensure approval of more life impacting drugs, by making the clinical development process much more efficient. For more than a decade Biorasi has focused on refining the process and execution of clinical trials, ensuring that three key variables – cost, time and risk – are optimized at every step. Our promise to our sponsors for every trial we run is: Biorasi combines the personal care and attention of a boutique CRO with the global capabilities of market-leading full-service organizations. With offices in most major regulatory jurisdictions, we have the ability to run trials across the world or in our backyard, as the specifics of the trial require. Our geographic distribution has given us experience across a wide range of regulatory environments, and in our time in the industry we’ve weathered all kinds of regulatory climates. Biorasi’s team understands the nuances of running trials in any given area or jurisdiction. We know, for example, that Type 2 Diabetes is diagnosed much earlier in the US than in India, or that informed consent is a personal decision in some jurisdictions and a family one in others. We know that some areas have frequent communications outages, and others are prone to work-stopping natural disasters during certain seasons of the year. We understand that patients view their doctors as gods in some countries, while patients in the US may not be so compliant with the doctor’s advice. Biorasi uses this understanding to inform decisions made on behalf of our sponsors to accelerate trial completion and regulatory approval. This global approach is just one of the many tools in our toolbox that helps us to deliver Clinical Research Optimized™. Biorasi has positioned itself uniquely in the industry, combining the responsiveness and attention to sponsor needs of the best small and niche CROs, with the global scale and full-service offerings of the best large CROs. This puts us in an ideal position to deliver on our promise of delivering Clinical Research Optimized ™. Biorasi is a new kind of CRO – one that doesn’t require sponsors to compromise hen choosing a CRO partner. At Biorasi, we have designed a contract research organization from the ground up to succeed where other CROs fail, and to deliver high-quality results in the most challenging trials. Our “new CRO” approach includes: Growing organically has given Biorasi the ability to create unified and consistent systems and processes, and resulting in better results for sponsors no matter which Biorasi team they’re working with. Biorasi is recognized as a leading expert in delivering success where other CROs fail. We are a trial rescue expert, recognized for our ability to complete trials that much larger CROs falter on. In our 15 years of experience, we've been able to rescue clinical trials from some of the leading names in pharma, lead by some of the most prominent contract research organizations in the world. Our rescue expertise doesn't just save our sponsors time and money - it saves entire drug development programs. Biorasi’s extremely capable and qualified internal management is bolstered by a board comprised of some of the most brilliant minds working in biopharma. Our directors and advisers help guide the company, and act as a vital strategic asset both for Biorasi and our sponsors. Dr. Kurt Ghelsen is a VP and the CSO at Research Corporation Technologies, an early-stage investment and management company specializing in biomedical companies and technologies. He has a long and distinguished career leading pharmaceutical companies, research centers and institutions, and non-profits. Dr. Ghelsen specializes in oncology and experimental medicine. Dr. Russel Kaufman is the Executive-in-Residence at Pappas Capital, an investment company focused solely on health and medicine. He also serves as the Emeritus professor of Medicine and Biochemistry at Duke University School of Medicine, and is the former president and CEO of The Wistar Institute, and holds leadership positions at the NIH, American Cancer Society, and the National Academy of Sciences. Doug Klinger is a health and internet executive with over 30 years of experience managing companies of all sizes and growth levels, including Monster, Cigna, and Sears Health and Wellness. He is an active investor, and is the CEO of Zelis Healthcare, an Inc. 500 company for the last 7 years. Robert Pearlman is the former president and CEO of the Diabetes Research Institute Foundation, a non-profit fundraising organization that provides capital for the Diabetes Research Institute at the University of Miami Miller School of Medicine. During his tenure at DRIF, the organization became the single largest contributor to the University of Miami in the school’s history. Eugene Golub is the founder and Chairman of the Board of Golub and Company, a visionary development company based out of Chicago. Recognized as being the first American developer to begin projects in Central and Eastern Europe and Russia in 1989, just prior to the return of market-driven economies to the region.